

Table 1. Demographic variables and clinical diagnosis of studied group

Item	No.=30
Age (days) *	36 (11-231)
Gestational age (week) *	32 (24-40)
≤ 28 week **	11 (36.7)
28-37 week **	10 (33.3)
>37 week **	9 (30)
Gender **	
Male	19 (63.3)
Birth weight * (gram)	2125 (440-3800)
Prematurity **	21 (70)
Prematurity and necrotising enterocolitis **	10 (33.3)
Congenital heart disease **	7 (23.3)
Congenital anomaly **	3 (10)
<u>Ichthyosis</u> **	2 (6.7)
Congenital pneumonia **	1 (3.3)
Fetal hypoxia **	1 (3.3)

*Median (min-max), ** n (%)

Table 2. Risk factors for invasive candidiasis

Item	No.=30
Extended spectrum antibiotic usage	30 (100)
Orogastric drainage	30 (100)
Mechanical ventilation	29 (96.7)
Total parenteral nutrition	28 (93.3)
Presence of central venous catheter	26 (86.7)
Premature rupture of membranes	20 (66.7)
Antenatal steroid usage	17 (56.7)
Fluconazole prophylaxis	16 (53.3)
History of surgery	16 (53.3)
Neutropenia	1 (3.3)

Table 3. Antifungal resistance pattern and MIC values of *Candida* spp. isolated from sterile samples

Cultured <i>Candida</i> spp.	Fluconazo le	Caspofungi n	Micafungin	Amphoteri cin B	Anidulafung in	Prior antifungal treatment	Culture negativit y (days)
<i>Candida</i> <i>glabrata</i>	resistant (12µg/ml)	intermediate resistant (0.25µg/ml)	sensitive (0.002µg/ml)	resistant (1.5µg/ml)	sensitive (0.016 µg/ml)	-	5
<i>Candida</i> <i>glabrata</i>	resistant (12µg/ml)	sensitive	sensitive (0.008µg/ml)	sensitive (1µg/ml)		fluconazol e	11
<i>Candida</i> <i>glabrata</i>	resistant	sensitive	sensitive	resistant		-	8
<i>Candida</i> <i>parapsilosis</i>	sensitive	intermediate resistant	sensitive	sensitive		-	6
<i>Candida</i> <i>parapsilosis</i>	sensitive	intermediate resistant	sensitive	sensitive		fluconazol e	4
<i>Candida</i> <i>guilliermo</i> <i>ndii</i>	sensitive	sensitive	sensitive	sensitive		fluconazol e	3
<i>Candida</i> <i>albicans</i>	sensitive	sensitive	sensitive	sensitive		fluconazol e	9
<i>Candida</i> <i>albicans</i>	sensitive	sensitive	sensitive	sensitive		-	1

MIC: Minimal inhibitory concentration

Table 4. Laboratory change before and after Micafungin treatment

Item	Before treatment	After treatment	p- value
Serum AST (IU/L)	28 (13-257)	37 (18-89)	0.86
Serum ALT (IU/L)	14 (6-180)	16 (6-50)	0.74
Serum creatinin (mg/dL)	0.5 (0.3-3.4)	0.5 (0.4-2.1)	0.42
Serum sodium (mmol/L)	136 (123-147)	136.5 (131-146)	0.56
Serum potassium (mmol/L)	4.4 (3.2-5.9)	4.37 (2.9-5.7)	0.14
Hemoglobin (gr/dL)	11.2 (6-15.1)	10.9 (7.3-14.5)	0.44
Leucocyte ($\times 10^3/\mu\text{L}$)	9.1 (3.2-33)	10.6 (2.1-47.6)	0.58
Trombocyte ($\times 10^3/\mu\text{L}$)	196.5 (17-613)	272 (19-937)	0.003*

*significant